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Prostate stromal tumor of uncertain malignant potential is a term used to describe a specialized pro-
liferation of stromal cells within the prostate. Most of these tumors tend to be benign, but some can
present with local invasion or progress to prostatic stromal sarcoma with distant metastasis. We report a
case of a 62-year-old male patient who presented to us with a diagnosis of stromal tumor of uncertain
malignant potential. We have followed up the patient for 5 years with imaging, prostate-speciﬁc antigen
checks, and annual prostate biopsies.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Stromal tumors of uncertain malignant potential (STUMPs) are
distinct rare lesions that were ﬁrst described in 1998 by Gaudin
et al.1 Although the term includes cases that may potentially be
benign, STUMPs are considered to be a neoplastic entity because of
their ability to recur, diffusely inﬁltrate the prostate gland with
possible extension to adjacent tissues, and progress to prostatic
stromal sarcoma (PSS) with possible distant metastasis.
Overall, these tumors are rare and have been described in only a
few case reports in patients aged 27-83 years. Presentation can vary
from lower urinary tract symptoms to elevated prostate-speciﬁc
antigen (PSA), hematuria, abnormal digital rectal examination,
and rectal obstruction.
Histologically, they are distinct from benign hyperplasia with
multiple subtypes being described, including degenerative atypia
with and without hypercellularity, myxoid pattern, and phyllodes
tumor. They fail to show any zonal predilection, and approxi-
mately 5% may progress to PSS, which has been reported with
metastasis to the lung and bone.1,2 Unfortunately, their behavior
cannot be predicted by their histologic appearance.3+1-215-662-7413.
.E. Kabarriti).
Inc.Open access under CC BY-NC-NImaging with an magnetic resonance imaging (MRI) can be
helpful in distinguishing between a localized proliferation vs a
mass-forming disease. Muglia et al4 described STUMP as diffusely
heterogeneous on T2-weighted images but with a homogeneous
low signal on T1-weighted images.Case presentation
We report a case of a 62-year-old male patient who presented
to us with an elevated PSA and a diagnosis of STUMP. He under-
went his ﬁrst biopsy at our institution in December 2008. We
have followed up the patient for 5 years with annual transrectal
ultrasound-guided prostate needle biopsies. In addition, the
patient has also undergone 4 surveillance endorectal MRIs during
this 5-year period for better characterization and local staging.
Over the past 5 years, his PSA has ranged between 2.49 and
4.49 ng/mL. His ﬁrst MRI was completed 2 days before his trans-
rectal ultrasound-guided prostate needle biopsy which revealed a
2.5-cm heterogeneous nodule with areas of high and low T2W
signal intensity in the posterior aspect of the prostate likely arising
from the central gland (Fig. 1). Prostate volume was 52 mL. At the
time of his biopsies, additional biopsies were taken from the
nodule, with pathology revealing persistent STUMP. The rest of the
prostate biopsies were benign prostatic tissue with atrophy.
Repeat annual biopsies of the nodule continued to reveal STUMP
without progression to PSS, whereas biopsies of the rest of pros-
tate continued to be benign. On the most recent MRI, his prostate
was found to have increased in size, with a signiﬁcant increase inD license.
Figure 1. MRI image demonstrating nodule with STUMP
Table 1
PSA trend with MRI and biopsy results
Date PSA
(ng/mL)
Number
of Prostate
Needle
Biopsy
Cores
MRI Prostate
Volume on
MRI (mL)
Size of
Nodule on
MRI (cm)
Presence
of STUMP
12/08 Not available 36 Yes 52 2.5 Yes
08/09 3.3 36 No Yes
07/10 2.81 32 Yes 40.3 2.2 Yes
07/11 2.49 33 Yes 41.9 2.7 Yes
08/12 3.79 30 Yes 68 6.4 Yes
11/13 4.49 20 No Yes
MRI, magnetic resonance imaging; PSA, prostate-speciﬁc antigen; STUMP, stromal
tumor of uncertain malignant potential.
A.E. Kabarriti et al. / Urology Case Reports 2 (2014) 43e4444the nodule from 2.7 cm in the largest dimension to 6.4 cm
(Table 1), but his biopsy results remain unchanged.
Discussion
STUMPs are infrequent prostatic tumors of mesenchymal
origin. To date, the etiology and pathogenesis of STUMP remain
unknown, whereas no risk factors have been clearly identiﬁed.
Although most of these cases tend to be indolent, varying degrees
of malignancy have been reported, including frequent local re-
currences with involvement of adjacent tissues and progression to
PSS with metastases to bone and lung.1 Patient presentation will
depend on the degree of local invasion and/or distant metastasis.
The diagnosis of STUMP is made histopathologically. However,
STUMP can bemisdiagnosed as benign prostatic hyperplasia (BPH)
or sarcoma. Similar to BPH, glandular crowding, papillary infold-
ing, and cyst formation may be present. However, other histologic
features, depending on the subtype of STUMP, can distinguish
STUMP form BPH. For example, in the degenerative atypia sub-
type, the most common subtype of STUMP, hypercellular stroma
with scattered atypical but degenerative cells are present in
addition to the common features with BPH.2 In contrast to sar-
coma, few or no mitotic ﬁgures are present.
The diagnosis of STUMP is important to recognize because of its
unpredictability and its malignant potential. Owing to its rarity,management for these lesions remains to be well deﬁned. Treat-
ment options can vary depending on the patient’s age, symptoms,
and preference for treatment vs surveillance. Management options
described in the literature have ranged from repeat transurethral
resections for obstructive symptoms to suprapubic and radical
prostatectomy. Our patient reported no symptoms with an Amer-
ican Urological Association score of 15/35, which he is satisﬁed
with. Although associations with adenocarcinoma and progression
to PSSs have been reported,5 our patient elected for close active
surveillance with annual biopsies and routine PSAs. In the absence
of signs of progression to prostatic sarcoma, we have not pursued
workup for metastatic disease.
To better identify the best treatment of STUMP, better charac-
terization and longer follow-up are needed. As the number of these
cases continues to accumulate, better understanding of this disease
will be possible.References
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